Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update #100 for 9/20/2021

9/20/2021

 
Our mission at Prescribe Right is to offer budget-friendly products that provide the information you need to proactively plan for budget-busting drugs. To commemorate our 100th COVID-19 update we are offering access to the knowledgebase for 100 hours or 100 days whichever comes first, for only $100. This offer expires at 11:59 pm on Friday, September 24, 2021.

Booster Vaccine Doses
  • In a review of data from 1,137,804 patients from the Israeli Ministry of Health database, found that a booster dose of the Pfizer/BioNTech COVID-19 vaccine, given at least five months after the second dose in patients 60 years or older, resulted in a reduction in confirmed and severe cases of COVID-19, during the first 12 days after the third dose.
  • In a six-month follow-up of the pivotal trial for the Pfizer/BioNTech COVID-19 vaccine (NCT04368728), vaccine efficacy was 91.3%.  Vaccine efficacy gradually decreased over time, but efficacy for severe disease remained high at 96.7% and 100% for the Beta variant. Overall efficacy was 84% from month four to six.
  • A third (booster) dose of the Pfizer/BioNTech COVID-19 vaccine was given to the pivotal trial population (NCT04368728), 7.9 to 8.8 months after the second dose. Antibody titers increased after the third dose for the original SARS-CoV-2 strain and variants.
  • A review by the FDA for the Vaccines and Related Biological Products Advisory Committee (VRBPAC) found a third dose of the Pfizer-BioNTech vaccine to be safe and well tolerated. The review questioned whether the available data and quality of the studies support a need for a third (booster) dose of the vaccine, since there is still adequate protection from severe COVID-19 and death.
  • The FDA VRBPAC voted 16 to 2 to recommend approval of a booster dose of the Pfizer-BioNtech COVID-19 vaccine, given 6-months after the second dose, in patients 65 years and older. The committee also voted 18 to 0 to recommend a booster dose for younger patients at high risk for severe COVID-19.​
COVID-19 Vaccines
 
ACIP recommended that COVID-19 vaccines can be coadministered with other vaccines, including influenza vaccines in their 2021–22 Influenza Season update.

Pfizer and BioNTech announced that in a 2,268 patient, Phase II/III trial (NCT04816643), two 10 mcg doses of their COVID-19 vaccine given 21 days apart, to children 5 to 11 years, produced antibody titers comparable to the levels seen with two 30 mcg adult doses in adolescents and young adults age 16 to 25 years. Data for children 2 to 5 years of age and children 6 months to 2 years of age is forecast to be available in the fourth quarter.

In a review of data from 1,736,832 patients from an Israeli managed care database, found the Pfizer/BioNTech COVID-19 vaccine increases the risk for lymphadenopathy, herpes zoster infection and appendicitis, while COVID-19 increases the risk for arrhythmia, acute kidney injury, pulmonary embolism, deep-vein thrombosis, myocardial infarction, pericarditis, and intracranial hemorrhage. While the vaccine increased the risk for myocarditis (2.7 events per 100,000 persons) the risk was over four times higher with COVID-19 (11.0 events per 100,000 persons).
 
COVID-19 Antibodies
 
The FDA expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab (Lilly) to include post-exposure prophylaxis in high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination and have been exposed COVID-19.
 
COVID-19 Antivirals
 
In the 15-day, 857 patient, Phase III, DisCoVeRy trial (NCT04315948), adding remdesivir to standard-of care did not improve clinical status (WHO seven-point ordinal scale) compared to standard-of-care alone in European hospitalized patients with COVID-19 for more than 7 days, who were receiving supplemental oxygen.

Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.